•
Dec 31, 2021

Sanara MedTech Q4 2021 Earnings Report

Announced fourth quarter and full year 2021 results.

Key Takeaways

Sanara MedTech reported record sales results in both the fourth quarter and the full year, building on the success of their Cellerate product line and executing their strategy to offer a comprehensive solution for wound and skin care in all care settings.

Built on the success of the Cellerate product line.

Executed strategy to offer a comprehensive solution for wound and skin in all care settings.

Achieved record sales results in both the fourth quarter and the full year.

Focused on providing patients with efficacious solutions that improve outcomes at a lower overall cost.

Total Revenue
$7.03M
Previous year: $4.79M
+46.9%
EPS
-$0.48
Previous year: -$0.04
+1100.0%
Gross Profit
$6.25M
Previous year: $4.3M
+45.4%
Cash and Equivalents
$18.7M
Previous year: $455K
+3996.2%
Free Cash Flow
-$1.93M
Previous year: -$1.08M
+78.7%
Total Assets
$36.4M
Previous year: $9.83M
+270.4%

Sanara MedTech

Sanara MedTech

Forward Guidance

No specific forward guidance was provided in the press release.